266 related articles for article (PubMed ID: 28461037)
1. Post-marketing drug withdrawals: Pharmacovigilance success, regulatory problems.
Aronson JK
Therapie; 2017 Oct; 72(5):555-561. PubMed ID: 28461037
[TBL] [Abstract][Full Text] [Related]
2. Post-marketing withdrawal of 462 medicinal products because of adverse drug reactions: a systematic review of the world literature.
Onakpoya IJ; Heneghan CJ; Aronson JK
BMC Med; 2016 Feb; 14():10. PubMed ID: 26843061
[TBL] [Abstract][Full Text] [Related]
3. Investigation assessing the publicly available evidence supporting postmarketing withdrawals, revocations and suspensions of marketing authorisations in the EU since 2012.
Lane S; Lynn E; Shakir S
BMJ Open; 2018 Jan; 8(1):e019759. PubMed ID: 29362275
[TBL] [Abstract][Full Text] [Related]
4. Post-Marketing Regulation of Medicines Withdrawn from the Market Because of Drug-Attributed Deaths: An Analysis of Justification.
Onakpoya IJ; Heneghan CJ; Aronson JK
Drug Saf; 2017 May; 40(5):431-441. PubMed ID: 28238125
[TBL] [Abstract][Full Text] [Related]
5. Strengthening and rationalizing pharmacovigilance in the EU: where is Europe heading to? A review of the new EU legislation on pharmacovigilance.
Borg JJ; Aislaitner G; Pirozynski M; Mifsud S
Drug Saf; 2011 Mar; 34(3):187-97. PubMed ID: 21332243
[TBL] [Abstract][Full Text] [Related]
6. Delays in the post-marketing withdrawal of drugs to which deaths have been attributed: a systematic investigation and analysis.
Onakpoya IJ; Heneghan CJ; Aronson JK
BMC Med; 2015 Feb; 13():26. PubMed ID: 25651859
[TBL] [Abstract][Full Text] [Related]
7. Post-marketing withdrawal of analgesic medications because of adverse drug reactions: a systematic review.
Onakpoya IJ; Heneghan CJ; Aronson JK
Expert Opin Drug Saf; 2018 Jan; 17(1):63-72. PubMed ID: 29076385
[TBL] [Abstract][Full Text] [Related]
8. Evaluation of patient reporting of adverse drug reactions to the UK 'Yellow Card Scheme': literature review, descriptive and qualitative analyses, and questionnaire surveys.
Avery AJ; Anderson C; Bond CM; Fortnum H; Gifford A; Hannaford PC; Hazell L; Krska J; Lee AJ; McLernon DJ; Murphy E; Shakir S; Watson MC
Health Technol Assess; 2011 May; 15(20):1-234, iii-iv. PubMed ID: 21545758
[TBL] [Abstract][Full Text] [Related]
9. Impact of Medicine Withdrawal on Reporting of Adverse Events Involving Therapeutic Alternatives: A Study from the French Spontaneous Reporting Database.
Pageot C; Bezin J; Smith A; Arnaud M; Salvo F; Haramburu F; Bégaud B; Pariente A;
Drug Saf; 2017 Nov; 40(11):1099-1107. PubMed ID: 28664354
[TBL] [Abstract][Full Text] [Related]
10. Post-marketing withdrawal of anti-obesity medicinal products because of adverse drug reactions: a systematic review.
Onakpoya IJ; Heneghan CJ; Aronson JK
BMC Med; 2016 Nov; 14(1):191. PubMed ID: 27894343
[TBL] [Abstract][Full Text] [Related]
11. Postmarketing withdrawal of human medicinal products because of adverse reactions in animals: a systematic review and analysis.
Onakpoya IJ; Heneghan CJ; Aronson JK
Pharmacoepidemiol Drug Saf; 2017 Nov; 26(11):1328-1337. PubMed ID: 28691251
[TBL] [Abstract][Full Text] [Related]
12. [Direct reporting by patients of adverse drug reactions in Spain].
Esther Salgueiro M; Jimeno FJ; Aguirre C; García M; Ordóñez L; Manso G
Farm Hosp; 2013; 37(1):65-71. PubMed ID: 23461502
[TBL] [Abstract][Full Text] [Related]
13. Testing the usefulness of the number needed to treat to be harmed (NNTH) in benefit-risk evaluations: case study with medicines withdrawn from the European market due to safety reasons.
Mendes D; Alves C; Batel Marques F
Expert Opin Drug Saf; 2016 Oct; 15(10):1301-12. PubMed ID: 27467204
[TBL] [Abstract][Full Text] [Related]
14. A Pharmacovigilance Signaling System Based on FDA Regulatory Action and Post-Marketing Adverse Event Reports.
Hoffman KB; Dimbil M; Tatonetti NP; Kyle RF
Drug Saf; 2016 Jun; 39(6):561-75. PubMed ID: 26946292
[TBL] [Abstract][Full Text] [Related]
15. The nature of the scientific evidence leading to drug withdrawals for pharmacovigilance reasons in France.
Olivier P; Montastruc JL
Pharmacoepidemiol Drug Saf; 2006 Nov; 15(11):808-12. PubMed ID: 16700082
[TBL] [Abstract][Full Text] [Related]
16. Adverse drug event surveillance and drug withdrawals in the United States, 1969-2002: the importance of reporting suspected reactions.
Wysowski DK; Swartz L
Arch Intern Med; 2005 Jun; 165(12):1363-9. PubMed ID: 15983284
[TBL] [Abstract][Full Text] [Related]
17. A description of signals during the first 18 months of the EMA pharmacovigilance risk assessment committee.
Pacurariu AC; Coloma PM; van Haren A; Genov G; Sturkenboom MC; Straus SM
Drug Saf; 2014 Dec; 37(12):1059-66. PubMed ID: 25398646
[TBL] [Abstract][Full Text] [Related]
18. Drug safety: withdrawn medications are only part of the picture.
Rawson NS
BMC Med; 2016 Feb; 14():28. PubMed ID: 26873482
[TBL] [Abstract][Full Text] [Related]
19. [Adverse drug reactions in pediatrics: Experience of a regional pharmacovigilance center].
Saint-Martin C; Kanagaratnam L; de Boissieu P; Azzouz B; Abou Taam M; Trenque T
Therapie; 2016 Oct; 71(5):467-473. PubMed ID: 27203165
[TBL] [Abstract][Full Text] [Related]
20. Post marketing surveillance of suspected adverse drug reactions through spontaneous reporting: current status, challenges and the future.
Alomar M; Tawfiq AM; Hassan N; Palaian S
Ther Adv Drug Saf; 2020; 11():2042098620938595. PubMed ID: 32843958
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
